parkinson's diseases

B2 (Linazolamide intermediate B impurity 2) promotes inclusion formation in cellular models of Huntington's disease and Parkinson's disease

1. Ginkgetin has anti-influenza virus and anti-fungal activities. 2. Ginkgetin has anti-inflammatory activity, can down-regulates COX-2 induction in vivo against skin inflammatory responses. 3. Ginkgetin is a good STAT3 inhibitor and may be a useful lead

PLX5622 is an orally active small-molecule CSF1R inhibitor that selectively depletes microglia in the brains of mice and rats. It is commonly used to establish models related to microglia-associated neuroinflammation, neurodegenerative diseases (such as Alzheimer's disease and Parkinson's disease), brain injury, and neuroimmune regulation. This product is also available as a premixed diet version (C2005 PLX5622 in AIN-76A Diet (1200 ppm)), eliminating the need for self-preparation and offering superior stability and reproducibility.

Paliroden is a non-peptide compound that can be taken orally and is used for supplementing neuro-nutrition. It stimulates the synthesis of endogenous neurotrophic factors and is employed in the research of neurodegenerative diseases such as Alzheimer's and Parkinson's.

E6801 is a novel selective 5-HT6 receptor agonist with a wide range of biological activities.E6801 can be used in the study of dementia, Parkinson's disease, depression, obesity epilepsy, anxiety, and many other diseases.

LRRK2-IN-7 (Compound 25) is a potent, highly selective, CNS-permeable LRRK2 kinase inhibitor with an IC₅₀ of 0.9 nM. LRRK2-IN-7 exhibits more than 1,000-fold selectivity over other kinases, ion channels, and CYP enzymes. LRRK2-IN-7 can be used in research on neurodegenerative diseases.

Nurr1 agonist 8 is a low-affinity Nurr1 agonist that can be used to study neurological diseases such as Parkinson's.

5-Bromo-2',3',5'-tri-O-acetyluridine is a purine nucleoside analog that is being explored to improve Alzheimer's and Parkinson's diseases.

Gcase activator 2 is a β-glucocerebrosidase activator that induces dimerization of GCase at the endoplasmic reticulum (ER) and lysosomal pHs, increases lysosomal substrate metabolism, and has therapeutic potential for the treatment of Parkinson's and Gosheimer's diseases.

MK-7337 is a high-affinity α-synuclein PET (positron emission tomography) ligand. Isotope-labeled MK-7337 serves as a PET tracer for imaging neurodegenerative diseases such as Parkinson's disease.

CZC-25146 (CHEMBL2397014) is an effective, specific and metabolically stable LRRK2 inhibitor with IC50 of 4.76/6.87 nM for wild-type LRRK2(Leucine-rich repeat kinase-2) and G2019S LRRK2, respectively.

GYKI 52466 dihydrochloride (GYKI 52466 2HCl) is a highly potent, orally active and selective AMPA/Kainate receptor antagonist with good blood-brain permeability and anticonvulsant activity that can be used to study neurological diseases such as Parkinson's and epilepsy.

P7C3 is a class of neuroprotective aminopropyl carbazoles which has been shown to block neuronal cell death in models of neurodegeneration. It was shown that P7C3 molecules additionally preserve axonal integrity after injury, before neuronal cell death occurs, in a rodent model of blast-mediated traumatic brain injury (TBI). This protective quality may be linked to the ability of P7C3 molecules to activate nicotinamide phosphoribosyltransferase, the rate-limiting enzyme in nicotinamide adenine dinucleotide salvage.

Kinetin triphosphate tetrasodium (KTP tetrasodium) is the tetrasodium salt form of Kinetin triphosphate, an ATP analog that enhances the activity of Parkinson's disease-associated mutant mitochondrial kinases PINK1(G309D) and PINK1(WT) and has therapeutic potential for neurodegenerative diseases.

MAO-B-IN-38 (Compound 6b) is a reversible, competitive inhibitor of MAO-B, exhibiting IC50 values of 0.03 µM for MAO-B and 21.46 µM for MAO-A. This compound is applicable in research on neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

DMPX (3,7-Dimethyl-1-propargylxanthine) is a caffeine-like compound capable of crossing the blood-brain barrier. It serves as an A2-selective adenosine receptor (AR) antagonist, effectively and selectively blocking the hypothermia and behavioral inhibition induced by A2 adenosine receptor agonists, such as NECA. DMPX is utilized in research on diseases like Parkinson's disease.

NRMA-9 is an amide prodrug of small molecule nuclear receptor modulators. It shows high exposure levels in the brain, indicating good penetration of the blood-brain barrier (BBB). NRMA-9 is utilized in research related to central nervous system diseases associated with nuclear receptors, such as Alzheimer's and Parkinson's.

Tyrosine kinase-IN-9 (Compound B) is an inhibitor of c-Abl. It is useful for studying neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

NRMA-I is an amide prodrug of a small molecule nuclear receptor modulator. It demonstrates high brain exposure, indicating effective blood-brain barrier (BBB) penetration. NRMA-I is useful for research into central nervous system diseases related to nuclear receptors, such as Alzheimer's and Parkinson's diseases.

NLRP3-IN-74 (Compound 11) is an orally active NLRP3 inhibitor with an IC50 of 2.7 μM. It significantly reduces IL-1β release by approximately 90% without affecting TNFα release. NLRP3-IN-74 is applicable in research on diseases such as atherosclerosis and Parkinson's disease.

hMAO-B-IN-11 (Compound 12) is a selective and reversible inhibitor of human monoamine oxidase B (hMAO-B) with an IC50 value of 0.11 µM. It operates by competitively binding to the active site of hMAO-B, thereby preventing the oxidative deamination of monoamines and reducing hydrogen peroxide production. Additionally, hMAO-B-IN-11 inhibits pro-inflammatory mediators (NO, TNF-α, IL-1β) in activated microglia. This compound holds potential for research in neurodegenerative diseases such as Parkinson's and Alzheimer's.

nNOS-IN-5 (Compound 9) is a potent inhibitor of human neuronal nitric oxide synthase (nNOS) with a Ki of 22 nM. It exhibits remarkable selectivity, being 900 times more selective for human nNOS over endothelial nitric oxide synthase (eNOS). nNOS-IN-5 is applicable in research related to neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

SARM1-IN-4 (Compound 7) is an orally active SARM1 inhibitor that reduces plasma neurofilament light chain (NfL) levels in a mouse model following a 50 mg/kg oral dose. By inhibiting the NAD+ hydrolase activity of SARM1, it prevents programmed axon degeneration, making it useful for research in neurodegenerative and neurological diseases such as multiple sclerosis, amyotrophic lateral sclerosis, Parkinson's disease, and peripheral neuropathy.

SARM1-IN-5 (compound 1-23-a) is an inhibitor of SARM1, useful for researching diseases related to axonal degeneration, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS).